This resource has been developed to provide practical information and advice on NICE medical technologies guidance on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.
It is intended to be used by both clinical and non‑clinical staff planning to implement this NICE guidance and start using this technology.
NICE's Adoption and Impact programme worked with NHS organisations to share their learning and experiences of using the UroLift system. The information presented in this resource is intended for the sole purpose of supporting the NHS in adopting, evaluating the impact of adopting or further researching this technology.
The information presented is complementary to the guidance and was not considered by the Medical Technologies Advisory Committee when developing its recommendations.
The UroLift system is designed to relieve symptoms of urinary outflow obstruction without cutting or removing tissue. The adjustable, permanent implants pull excess prostatic tissue away so that it does not narrow or block the urethra. The procedure is minimally invasive and an alternative to current standard surgical interventions for symptoms of benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate. It is indicated for use in men aged 50 years and older and is contraindicated in men who have prostates larger than 100 ml and in men whose prostate has an obstructing middle lobe.
The benefits of using the UroLift system as reported by the NHS staff involved in producing this resource include:
Potential cost savings because of fewer inpatient bed days; pre‑operative process costs and follow‑up appointments.
Faster procedure time (particularly if done under local anaesthetic and without catheter), leading to increased capacity.
Improved quality of life because of reduced post‑operative pain, reduced recovery period and preserved sexual function.
Greater choice for men at the surgical stage of their pathway which does not increase risk for further surgical interventions.
Improved symptom control in men with multiple comorbidities for whom surgery is unsuitable.
The learning gained from existing users is presented as a series of examples of current practice. They are not presented as best practice but as real‑life examples of how NHS sites have adopted this technology.
This page was last updated: 27 April 2017